EMA Authorised: Champix (varenicline) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Champix (varenicline) for tobacco use cessation in the European Union, with Pfizer Europe MA EEIG as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Champix (varenicline)

Snippet

Status: Authorised. Therapeutic area: Tobacco Use Cessation. MAH: Pfizer Europe MA EEIG. Decision date: 10/09/2025